PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

Genomic Profiling of Breast Cancer in African-American Women Using MammaPrint.

PUBLICATION: Breast Cancer Res Treat (2016) 159: 481. https://doi.org/10.1007/s10549-016-3949-y09. AUTHORS: Raquel A. Nunes, Lynette Wray, Mihriye Mete, Pia Herbolsheimer, Karen L. Smith, Lana Bijelic, Marc E. Boisvert, Sandra M. Swain SUMMARY: We evaluated gene expression in tumors from AAF presenting with early stage or locally advanced breast cancer using MammaPrint, Read More

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

PUBLICATION: N Engl J Med 2016; 375:717-729; DOI: 10.1056/NEJMoa1602253. AUTHORS: Fatima Cardoso, M.D., Laura J. van’t Veer, Ph.D., Jan Bogaerts, Ph.D., Leen Slaets, Ph.D., Giuseppe Viale, M.D., Suzette Delaloge, M.D., Jean-Yves Pierga, M.D., Ph.D., Etienne Brain, M.D., Ph.D., Sylvain Causeret, M.D., Mauro DeLorenzi, Ph.D., Annuska M. Glas, Ph.D., Vassilis Golfinopoulos, Read More

MINDACT Supplementary Appendix NEJM 2016

SUPPLEMENTARY APPENDIX: This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Cardoso F., van’t Veer L.J., Bogaerts J., et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016;375:717-29. DOI: 10.1056/NEJMoa1602253.   Read Read More

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

PUBLICATION: Ann Surg Oncol (2016) 23: 3317. https://doi.org/10.1245/s10434-016-5329-6. AUTHORS: Peter Beitsch, Pat Whitworth, Paul Baron, James Pellicane, Tina Treece, Erin Yoder, Mark Gittleman, NBRST Investigators Group SUMMARY: This substudy showed that NAT significantly altered the genomic signature of the patient's breast cancer compared with the patient's pre-treatment genomic profile. These Read More

Breast Cancer: Determining the Genetic Profile from Ultrasound-Guided Percutaneous Biopsy Specimens Obtained During Diagnostic Workups

PUBLICATION: Radiología (English Edition) Volume 58, Issue 3, May–June 2016, Pages 214-220. AUTHORS: J.A. López Ruiz, I.Zabalza Estévez, J.A. Mieza Arana SUMMARY: Small study demonstrating feasbility of MP on FFPE core biopsies -13 patients. Read more: López Ruiz et al_2016_Radiología_Breast Cancer: Determining the Genetic Profile...  

Cáncer de Mama: Determinación del Perfil Genético a Partir de la Biopsia Percutánea Ecoguiada Diagnóstica

PUBLICATION: Radiología; Vol. 58. Issue 3. pages 214-220 (May-June 2016) AUTHORS: J.A. López Ruiza, I. Zabalza Estévezb, J.A. Mieza Aranac PUBLICATION TITLE (English): Breast cancer: determining the genetic profile from ultrasound-guided percutaneous biopsy specimens obtained during the diagnostic workups ABSTRACT: Objectives: To evaluate the possibility of determining the genetic profile Read More

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy

PUBLICATION: Ann Surg Oncol (2016) 23: 1522. https://doi.org/10.1245/s10434-015-5030-1. AUTHORS: Paul Baron, Peter Beitsch, Danielle Boselli, James Symanowski, James V. Pellicane, Jennifer Beatty, Paul Richards, Angela Mislowsky, Charles Nash, Laura A. Lee, Mary Murray, Femke A. de Snoo, Lisette Stork-Sloots, Mark Gittleman, Stephanie Akbari, Pat Whitworth SUMMARY: We found that although Read More